Bulletin
Investor Alert

Horizon Therapeutics PLC

NAS: HZNP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 31, 2023, 7:59 p.m.

/zigman2/quotes/206690250/composite

$

109.75

Change

+0.03 +0.03%

Volume

Volume 405,817

Quotes are delayed by 20 min

/zigman2/quotes/206690250/composite

Today's close

$ 110.05

$ 109.72

Change

-0.33 -0.30%

Day low

Day high

$108.01

$110.75

Open

52 week low

52 week high

$57.84

$117.49

Open

Company Description

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUIN...

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Valuation

P/E Current

48.53

P/E Ratio (with extraordinary items)

45.11

P/E Ratio (without extraordinary items)

47.52

Price to Sales Ratio

7.87

Price to Book Ratio

5.24

Price to Cash Flow Ratio

24.53

Enterprise Value to EBITDA

25.26

Enterprise Value to Sales

7.04

Efficiency

Total Asset Turnover

0.44

Liquidity

Current Ratio

3.08

Quick Ratio

2.83

Cash Ratio

1.79

Profitability

Gross Margin

75.37

Operating Margin

21.02

Pretax Margin

14.34

Net Margin

16.57

Return on Assets

7.25

Return on Equity

12.29

Return on Total Capital

10.92

Capital Structure

Total Debt to Total Assets

30.75

Officers and Executives

Name Age Officer Since Title
Mr. Timothy P. Walbert 53 2008 Chairman, President & Chief Executive Officer
Mr. Aaron L. Cox 39 2016 Executive Vice President-Finance
Dr. Karin Rosen - 2020 Chief Scientific Officer
Dr. Elizabeth H. Z. Thompson 46 2018 Executive Vice President-Research & Development
Dr. Jeffrey W. Sherman 66 2009 Chief Medical Officer & Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/11/2023 Jeffrey W. Sherman
EVP and Chief Medical Officer
3,368   Disposition at $113.1 per share. 380,920
01/10/2023 Jeffrey W. Sherman
EVP and Chief Medical Officer
3,368   Disposition at $113.05 per share. 380,752
01/06/2023 Jeffrey W. Sherman
EVP and Chief Medical Officer
5,187   Disposition at $113.29 per share. 587,635
01/05/2023 Timothy P. Walbert
Chairman, President and CEO; Director
97,461   Derivative/Non-derivative trans. at $113.24 per share. 11,036,483
01/05/2023 Michael A. DesJardin
EVP, Technical Operations
26,901   Derivative/Non-derivative trans. at $113.24 per share. 3,046,269
01/05/2023 Patrick McIlvenny
Chief Accounting Officer
4,147   Derivative/Non-derivative trans. at $113.24 per share. 469,606
01/05/2023 Timothy P. Walbert
Chairman, President and CEO; Director
219,995   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2023 Michael A. DesJardin
EVP, Technical Operations
54,253   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2023 Patrick McIlvenny
Chief Accounting Officer
7,973   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 Timothy P. Walbert
Chairman, President and CEO; Director
46,365   Derivative/Non-derivative trans. at $113.8 per share. 5,276,337
01/01/2023 Jeffrey W. Sherman
EVP and Chief Medical Officer
9,717   Derivative/Non-derivative trans. at $113.8 per share. 1,105,794
01/01/2023 Michael A. DesJardin
EVP, Technical Operations
9,561   Derivative/Non-derivative trans. at $113.8 per share. 1,088,041
01/01/2023 Timothy P. Walbert
Chairman, President and CEO; Director
104,498   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 Jeffrey W. Sherman
EVP and Chief Medical Officer
21,772   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 Michael A. DesJardin
EVP, Technical Operations
21,772   Derivative/Non-derivative trans. at $0 per share. 0
12/30/2022 Andy Pasternak
EVP, Chief Strategy Officer
39,313   Derivative/Non-derivative trans. at $113.8 per share. 4,473,819
12/30/2022 Aaron L. Cox
EVP, Chief Financial Officer
28,758   Derivative/Non-derivative trans. at $113.8 per share. 3,272,660
12/30/2022 Elizabeth H. Z. Thompson
EVP, Research & Development
9,449   Derivative/Non-derivative trans. at $113.8 per share. 1,075,296
12/30/2022 Jeff Himawan
Director
2,230   Gift at $0 per share. 0
12/30/2022 Andy Pasternak
EVP, Chief Strategy Officer
88,733   Derivative/Non-derivative trans. at $0 per share. 0
12/30/2022 Aaron L. Cox
EVP, Chief Financial Officer
64,906   Derivative/Non-derivative trans. at $0 per share. 0
12/30/2022 Elizabeth H. Z. Thompson
EVP, Research & Development
19,055   Derivative/Non-derivative trans. at $0 per share. 0
12/15/2022 Aaron L. Cox
EVP, Chief Financial Officer
4,774   Gift at $0 per share. 0
12/13/2022 Andy Pasternak
EVP, Chief Strategy Officer
6,918   Disposition at $112.6 per share. 778,966
12/13/2022 Andy Pasternak
EVP, Chief Strategy Officer
23,251   Disposition at $112.61 per share. 2,618,295
12/13/2022 Andy Pasternak
EVP, Chief Strategy Officer
23,251   Derivative/Non-derivative trans. at $29.52 per share. 686,369
12/12/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
21,378   Disposition at $111.45 per share. 2,382,578
12/12/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
6,974   Disposition at $111.44 per share. 777,182
11/01/2022 Andy Pasternak
EVP, Chief Strategy Officer
5,503   Derivative/Non-derivative trans. at $63.18 per share. 347,679
11/01/2022 Andy Pasternak
EVP, Chief Strategy Officer
12,421   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/hznp

MarketWatch News on HZNP

  1. Amgen’s Q4 tops views, but 2023 guidance falls on lower end of expectations

    4:44 p.m. Today

    - Claudia Assis

  2. Is pharma M&A making a comeback?

    7:22 a.m. Jan. 13, 2023

    - Jaimy Lee

  3. The Year's Biggest Healthcare Conference Starts Today

    8:44 a.m. Jan. 9, 2023

    - Josh Nathan-Kazis

  4. Why Atlanta Tops the Hottest 2023 Real Estate Markets

    8:01 p.m. Dec. 16, 2022

    - Liz Lucking

  5. Why Deal Making Will Rebound in 2023

    3:19 p.m. Dec. 16, 2022

    - Carleton English

  6. M&A Could Recover Next Year. These Stocks Could Benefit. 

    1:30 a.m. Dec. 13, 2022

    - Jacob Sonenshine

  7. Why Amgen Fought So Hard to Buy Horizon

    10:37 a.m. Dec. 12, 2022

    - Joe Woelfel

  8. Horizon Therapeutics stock up 14% premarket

    6:06 a.m. Dec. 12, 2022

    - Ciara Linnane

  9. Amgen to pay $116.50 for each Horizon share for a 47.9% premium over closing price Nov.29, before deal first mooted

    6:04 a.m. Dec. 12, 2022

    - Ciara Linnane

  10. Amgen confirms to acquire Horizon Therapeutics in deal valued at about $27.8 bln

    6:03 a.m. Dec. 12, 2022

    - Ciara Linnane

  11. Amgen reportedly in talks to buy Horizon Therapeutics

    1:36 a.m. Dec. 12, 2022

    - Ben Dummett

  12. Loading more headlines...
/news/nonmarketwatch/company/us/hznp

Other News on HZNP

  1. Top 5 4th Quarter Trades of WRIGHT INVESTORS SERVICE INC

    6:00 p.m. Jan. 27, 2023

    - GuruFocus.com

  2. Top 5 4th Quarter Trades of DELTEC ASSET MANAGEMENT LLC

    6:00 p.m. Jan. 25, 2023

    - GuruFocus.com

  3. Top 5 4th Quarter Trades of HAVENS ADVISORS LLC

    2:00 p.m. Jan. 25, 2023

    - GuruFocus.com

  4. FIRST HAWAIIAN BANK Buys 2, Sells 3 in 4th Quarter

    4:00 p.m. Jan. 12, 2023

    - GuruFocus.com

  5. Drugmakers Spent Freely in 2022 to Protect Revenue

    5:30 a.m. Dec. 30, 2022

    - Jared S. Hopkins

  6. Healthcare Deal-Making Set to Surge in 2023

    7:00 a.m. Dec. 27, 2022

    - David Wainer

  7. This Healthcare Stock Just Boosted Its Dividend by 10%

    11:06 a.m. Dec. 19, 2022

    - Baystreet.ca

  8. How Horizon Therapeutics Will Strengthen Amgen's Portfolio

    1:32 p.m. Dec. 14, 2022

    - GuruFocus.com

  9. Horizon Jumps 15% on $26 Billion Acquisition Deal

    5:14 p.m. Dec. 13, 2022

    - GuruFocus.com

  10. Amgen Hunts for New Revenue in $28 Billion Deal

    5:26 p.m. Dec. 12, 2022

    - Joseph Walker

  11. Amgen Hunts for New Revenue in $28 Billion Deal

    4:28 p.m. Dec. 12, 2022

    - Joseph Walker

  12. First Test for Amgen: Fix Horizon’s Growth Problem

    12:10 p.m. Dec. 12, 2022

    - David Wainer

  13. Wall Street Awaits Key Fed FOMC Decision

    10:57 a.m. Dec. 12, 2022

    - Zacks.com

  14. Busy Week Highlighted by Next Fed Rate Move

    10:34 a.m. Dec. 12, 2022

    - Zacks.com

  15. Loading more headlines...

At a Glance

Horizon Therapeutics Plc

70 St. Stephen's Green

Dublin, Dublin 4

Phone

353 17722100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$3.23B

Net Income

$534.49M

Employees

1,890

/news/pressrelease/company/us/hznp

Press Releases on HZNP

  1. Rule 17 (b) Announcement – Horizon Therapeutics plc

    6:05 p.m. Jan. 23, 2023

    - BusinessWire - BZX

  2. Rule 17 (a) Announcement – Horizon Therapeutics plc

    6:01 p.m. Jan. 23, 2023

    - BusinessWire - BZX

  3. Rule 2.12 Announcement – Horizon Therapeutics plc

    5:05 p.m. Jan. 12, 2023

    - BusinessWire - BZX

  4. Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

    11:55 a.m. Jan. 6, 2023

    - BusinessWire - BZX

  5. Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

    11:45 a.m. Jan. 6, 2023

    - BusinessWire - BZX

  6. Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

    11:41 a.m. Jan. 6, 2023

    - BusinessWire - BZX

  7. Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

    11:25 a.m. Jan. 6, 2023

    - BusinessWire - BZX

  8. Loading more headlines...
Link to MarketWatch's Slice.